Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.55 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL744076 | 0.94 | HTR6 (0.50) | HTR6ASIC3CYP3A4HTR2CHTR2A | |
| SCHEMBL741800 | 0.89 | HTR6 (0.52) | HTR6ASIC3CYP3A4HTR2CHTR2A | |
| SCHEMBL742225 | 0.87 | HTR6 (0.55) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL743065 | 0.85 | HTR6 (0.42) | HTR6CYP3A4HTR2C | |
| SCHEMBL742112 | 0.85 | HTR6 (0.58) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL744445 | 0.84 | HTR6 (0.61) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL14070202 | 0.84 | HTR6 (0.47) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL743069 | 0.84 | HTR6 (0.49) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| SCHEMBL742660 | 0.83 | HTR6 (0.53) | HTR6CYP3A4HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL743367 | 0.83 | HTR6 (0.47) | HTR6CYP3A4HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| CN-111529526-A | Application of compound in preparation of medicine for treating acute pancreatitis | 广州领晟医疗科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| CN-111514137-A | Application of compound in preparation of medicine for treating acute lung injury | 广州领晟医疗科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-2137163-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-03-18 | — | — | EP | claimed |
| US-20150011576-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | claimed |
| US-8841315-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2014-09-23 | — | — | US | claimed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-12 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-6670334-B2 | Antiinflammatory agent | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-12-30 | — | — | US | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| US-20020111327-A1 | Method and compositions for treating the inflammatory response | VIRGINIA, UNIVERSITY OF | 2002-08-15 | — | — | US | claimed |
| EP-0651027-B1 | Azodyestuffs of the stilbene series | CLARIANT FINANCE BVI LTD (VG) | 1999-08-18 | — | — | EP | claimed |
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | claimed |
| EP-0679173-B1 | AZO COMPOUND | ZENECA LTD (GB) | 1997-12-03 | — | — | EP | claimed |
| EP-0651027-A1 | Disazo dyestuffs of the stilbene series | SANDOZ LTD. (CH) | 1995-05-03 | — | — | EP | claimed |
| WO-1994016021-A1 | AZO COMPOUND | ZENECA LIMITED (GB) | 1994-07-21 | — | — | WO | claimed |
| EP-0559371-A1 | Method of reducing the concentration of a liquid resin in an aqueous composition | THE DOW CHEMICAL COMPANY (US) | 1993-09-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK5 | HTR6 3573/4885ASIC3 3809/4885CYP3A4 4636/4885 |
| US-20020111327-A1 | Method and compositions for treating the inflammatory response | PDE4A, PDE7A, PDE2A | HTR6 823/4885ASIC3 1604/4885CYP3A4 1493/4885 |
| US-20150011576-A1 | Inhibitors of Protein Kinases | CDK1, CDK2, CDK5 | HTR6 3573/4885ASIC3 3809/4885CYP3A4 4636/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | HTR6 97/4885ASIC3 4027/4885CYP3A4 255/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | HTR6 2722/4885ASIC3 4048/4885CYP3A4 885/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | HTR6 2319/4885ASIC3 1592/4885CYP3A4 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.